Dogwood Therapeutics (DWTX) vs Pliant Therapeutics (PLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pliant Therapeutics (PLRX) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 61.6% versus a loss of 83.7%. Over five years, PLRX leads with a -95.9% price change compared with -99.2% for DWTX. Dogwood Therapeutics is the larger company by market cap ($39.6 million vs $36.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DWTX | PLRX |
|---|---|---|
| Share price | $1.04 | $0.5951 |
| Market cap | $39.57M | $36.89M |
| 1-day change | -2.36% | -4.02% |
| YTD return | -75.12% | -51.22% |
| 1-year return | -83.68% | -61.61% |
| 5-year return | -99.16% | -95.89% |
| P/E ratio (TTM) | 0.10 | — |
| EPS (TTM) | $10.26 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-34.26M | $-149.34M |
| 52-week high | $7.04 | $1.67 |
| 52-week low | $0.901 | $0.5719 |
| Distance from 52-week high | -85.31% | -64.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +1252.66% | +236.08% |
| Average volume | 89.88K | 408.93K |
| Shares outstanding | 38.23M | 61.99M |
| Employees | 8 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRX has outperformed DWTX by 22.1 percentage points over the past year.
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
DWTX vs PLRX FAQ
Which is bigger, Dogwood Therapeutics or Pliant Therapeutics?
Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $39.57M compared with $36.89M for Pliant Therapeutics (PLRX).
Which stock has performed better over the past year, DWTX or PLRX?
PLRX returned -61.61% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Are Dogwood Therapeutics and Pliant Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.